Clinical trials: Streptococcus Pneumoniae
Pneumococcal Infection
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.
- Trial name
- NCT00560950
- Testing
- pneumococcal 23v polysaccharide vaccine
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Mother's Gift Project
This prospective randomized evaluation of pneumococcal vaccine immunization of pregnant mothers, followed by pneumococcal conjugate immunization of their children is designed to assess the effects of these strategies on the…
- Trial name
- NCT00142389
- Testing
- pneumococcal polysaccharide and protein conjugate vaccines
- Where
- Bangladesh
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
CKD (Chronic Kidney Disease) Stage 5D, Pneumonia
Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients
The investigators compare two strata of vaccinated patients: those recently vaccinated and those vaccinated more than two years ago. The primary objective is to compare pneumonia rates between the groups.
- Trial name
- DOPPIO (NCT03350425)
- Where
- 12 sites in Germany
- Volunteers
- 792 people
- Sponsor
- University of Cologne
Pneumococcal Infections
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
- Trial name
- NCT05667740
- Testing
- Gamma-PN3, Prevenar-13, Pneumovax-23
- Where
- Australia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumonia
Pneumococcal Adult-dose Ranging Immunization Study
The purpose of this study is to give seniors different doses of a new pneumococcal vaccine called PCV7 to evaluate the safety of the vaccine and compare the immune response to find out which amount gives the best immune response.
- Trial name
- NCT00169234
- Testing
- PCV7, Prevnar®, Pneumovax 23
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Kaiser Permanente
Healthy Volunteers
Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects
The purpose of this study is to evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly to Japanese healthy adults 20 to 49 years of age.
- Trial name
- NCT04265911
- Testing
- ASP3772 (subcutaneous), ASP3772 (intramuscular), PPSV23 (subcutaneous)
- Where
- Japan
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Affinivax, Inc.
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Safety and Local Tolerability of Prevenar in Indian Children
This postmarketing surveillance study will evaluate the safety profile of Prevenar in Indian children. Prevenar is indicated for active immunization of infants and children from 6 weeks of age through 9 years of age against…
- Trial name
- NCT00488800
- Testing
- pneumococcal conjugate vaccine
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Streptococcus Pneumonia, Controlled Human Infection
Experimental Human Pneumococcal Challenge With SPN3
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past…
- Trial name
- Challenge3 (NCT05535868)
- Testing
- Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3), Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Infections, Streptococcal
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
To evaluate the immunological memory against pneumococcal vaccine serotypes in children primed with conjugate vaccines by administering a booster dose of plain polysaccharide vaccine.
- Trial name
- NCT00333450
- Testing
- Pneumococcal vaccine
- Where
- 30 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Otorrhea
Bacteriological Evaluation of Children With Otorrhea
After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood.
- Trial name
- NCT04807660
- Testing
- middle ear fluid sample for bacterial analysis (conventional microbiology analysis)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections, Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114…
- Trial name
- PNEU-PED (NCT03893448)
- Testing
- V114, Prevnar 13™, RotaTeq™
- Where
- 81 sites in United States, Puerto Rico and 2 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcus Pneumoniae
Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
The present study intends to investigate the use as a booster of a dose of sanofi pasteur's Pneumo 23 vaccine in the second year of life following 3-dose priming with Wyeth's Prevnar vaccine.
- Trial name
- NCT00594347
- Testing
- Pneumo 23, Prevnar
- Where
- 2 sites in Thailand
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary…
- Trial name
- NCT01235949
- Testing
- GSK1024850A (SynflorixTM), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 23 sites in Romania
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
The group aged 18-59 years old, the group ≥60 years old, and the group aged 2-17 years old were successively assigned to the group.
- Trial name
- NCT05815264
- Testing
- 23-valent pneumococcal polysaccharide vaccine, pneumococcal vaccine polyvalent
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
HIV Infections
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and…
- Trial name
- NCT00002392
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockefeller University
Lymphoma
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
- Trial name
- NCT06049134
- Testing
- PCV20
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Pneumococcal Infections
Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine
This is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunogenicity…
- Trial name
- NCT05477693
- Testing
- Experimental 23-valent PPV, Control 23-valent PPV
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited